These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37639271)

  • 21. Diagnostic accuracy and added value of blood-based protein biomarkers for pancreatic cancer: A meta-analysis of aggregate and individual participant data.
    Boyd LNC; Ali M; Leeflang MMG; Treglia G; de Vries R; Le Large TYS; Besselink MG; Giovannetti E; van Laarhoven HWM; Kazemier G
    EClinicalMedicine; 2023 Jan; 55():101747. PubMed ID: 36457649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
    Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access GI Monitor assay on the UniCel Dxl 800 Immunoassay System.
    Stieber P; Molina R; Gion M; Gressner A; Troalen F; Holdenrieder S; Auge JM; Zancan M; Wycislo M; Jarrige V
    Clin Chem Lab Med; 2008; 46(5):600-11. PubMed ID: 18598202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.
    Koopmann J; Buckhaults P; Brown DA; Zahurak ML; Sato N; Fukushima N; Sokoll LJ; Chan DW; Yeo CJ; Hruban RH; Breit SN; Kinzler KW; Vogelstein B; Goggins M
    Clin Cancer Res; 2004 Apr; 10(7):2386-92. PubMed ID: 15073115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer.
    Reitz D; Gerger A; Seidel J; Kornprat P; Samonigg H; Stotz M; Szkandera J; Pichler M
    J Clin Pathol; 2015 Jun; 68(6):427-33. PubMed ID: 25759406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.
    Luo G; Fan Z; Cheng H; Jin K; Guo M; Lu Y; Yang C; Fan K; Huang Q; Long J; Liu L; Xu J; Lu R; Ni Q; Warshaw AL; Liu C; Yu X
    Pancreatology; 2018 Dec; 18(8):971-976. PubMed ID: 30131287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer.
    Wang WS; Liu LX; Li GP; Chen Y; Li CY; Jin DY; Wang XL
    Cancer Prev Res (Phila); 2013 Apr; 6(4):331-8. PubMed ID: 23430754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
    Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.
    Singh S; Tang SJ; Sreenarasimhaiah J; Lara LF; Siddiqui A
    Dig Dis Sci; 2011 Aug; 56(8):2491-6. PubMed ID: 21516323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
    Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
    Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative Albumin-Bilirubin Grade as a Useful Prognostic Indicator in Patients With Pancreatic Cancer.
    Yagyu T; Saito H; Sakamoto T; Uchinaka EI; Morimoto M; Amisaki M; Watanabe J; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
    Anticancer Res; 2019 Mar; 39(3):1441-1446. PubMed ID: 30842180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
    Mann DV; Edwards R; Ho S; Lau WY; Glazer G
    Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
    Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
    Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy of simultaneous measurement of serum biomarkers: Carbohydrate antigen 19-9, pancreatic elastase-1, amylase, and lipase for diagnosing pancreatic ductal adenocarcinoma.
    Yang CY; Lin RT; Chen CY; Yeh CC; Tseng CM; Huang WH; Lee TY; Chu CS; Lin JT
    J Formos Med Assoc; 2022 Dec; 121(12):2601-2607. PubMed ID: 35918272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
    Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
    J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score.
    Dumitra S; Jamal MH; Aboukhalil J; Doi SA; Chaudhury P; Hassanain M; Metrakos PP; Barkun JS
    HPB (Oxford); 2013 Dec; 15(12):1002-9. PubMed ID: 23521164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer.
    Tanaka H; Tamura K; Abe T; Yoshida T; Macgregor-Das A; Dbouk M; Blackford AL; Borges M; Lennon AM; He J; Burkhart R; Canto MI; Goggins M
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2267-2275.e2. PubMed ID: 34648951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning.
    Kawai M; Fukuda A; Otomo R; Obata S; Minaga K; Asada M; Umemura A; Uenoyama Y; Hieda N; Morita T; Minami R; Marui S; Yamauchi Y; Nakai Y; Takada Y; Ikuta K; Yoshioka T; Mizukoshi K; Iwane K; Yamakawa G; Namikawa M; Sono M; Nagao M; Maruno T; Nakanishi Y; Hirai M; Kanda N; Shio S; Itani T; Fujii S; Kimura T; Matsumura K; Ohana M; Yazumi S; Kawanami C; Yamashita Y; Marusawa H; Watanabe T; Ito Y; Kudo M; Seno H
    Br J Cancer; 2024 Oct; 131(7):1158-1168. PubMed ID: 39198617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer.
    Kitagawa T; Taniuchi K; Tsuboi M; Sakaguchi M; Kohsaki T; Okabayashi T; Saibara T
    Mol Oncol; 2019 Feb; 13(2):212-227. PubMed ID: 30358104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.